Professional
Added to YB: 2025-10-22
Pitch date: 2025-10-20
LQDA [neutral]
Liquidia Corporation
+193.05%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$7.1B
Pitch Price
$24.25
Price Target
100.00 (+33%)
Dividend
N/A
EV/EBITDA
40.62
P/E
53.31
EV/Sales
15.42
Sector
Pharmaceuticals
Category
special_situation
Arquitos Capital Management Portfolio Holding: Liquidia Corporation
LQDA (holding update): FDA approved Yutrepia (inhaled treprostinil for PAH/PH-ILD) launched exceptionally - 900+ unique prescriptions, 550+ patient starts in 11 weeks, exceeding CEO expectations. Shares mispriced due to conservative analyst estimates & '327 patent litigation uncertainty. Bull case $100/share, base case $75 by 2027.
Read full article (2 min)